Bulbine Natalensis - Dabrafenib Interaction Details

Interaction Details

Dabrafenib is classified as belonging to the following category: Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, Bulbine natalensis stem might reduce the levels and clinical effects of CYP3A4 substrates.
In vitro research shows that Bulbine natalensis stem extract induces CYP3A4 mRNA expression and enzyme activity. Theoretically, this may increase the metabolism of CYP3A4 substrates, but this has not been studied in humans.

Interaction Rating

Moderate

Likelihood of Occurrence

Possible

Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists

References

Husain I, Dale OR, Manda V, et al. Bulbine natalensis (currently Bulbine latifolia) and select bulbine knipholones modulate the activity of AhR, CYP1A2, CYP2B6, and P-gp. Planta Med 2022;88(12):975-984.

Dabrafenib Overview

Dabrafenib is used alone or in combination with trametinib (Mekinist) to treat a certain types of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. It is also used along with trametinib to treat and prevent the return of a certain type of melanoma after surgery to remove it and any affected lymph nodes. Dabrafenib is also used in combination with trametinib to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body. It is also used to treat a certain type of thyroid cancer that has spread to nearby tissues or to other parts of the body that has not responded to previous treatment(s). Dabrafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.

See More Information Regarding Dabrafenib

Bulbine Natalensis - More Interactions

Bulbine Natalensis interacts with 893 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.

Major	The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur.
Moderate	Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur.
Minor	Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction.
Unknown	No interactions have been reported or no interaction data is currently available.